AI assistant
Transgene — Regulatory Filings 2024
Jan 4, 2024
1715_rns_2024-01-04_b1728bf6-1257-4cc2-b9d9-65762c7bccd3.pdf
Regulatory Filings
Open in viewerOpens in your device viewer
PRESS RELEASE
Balance sheet of the liquidity contract with Natixis Oddo BHF SCA as of December 31, 2023
Strasbourg, January 4, 2024 – 05:45 pm CET
Under the liquidity contract entrusted by Transgene to Natixis Oddo BHF SCA, as of December 31, 2023, the following resources were managed through the liquidity account:
- 303,861 shares
- € 125,121.00
In the second half of 2023, a total of:
| Purchases | 157,564 shares |
€ 249,580 | 651 market transactions |
|---|---|---|---|
| Sales | 133,103 shares |
€ 219,772 | 613 market transactions |
It is recalled that when the liquidity program was initially established in 2016, the following resources were made available:
Cash balance of the liquidity contract: € 500,000.00
At the time the liquidity program was transferred to Natixis Oddo BHF SCA on January 2, 2020, the resources managed through the liquidity account consisted of:
- 164,183 shares
- € 246,158.00
Contacts
Transgene:
Arnaud DUBARRY CFO +33 (0)3 88 27 91 00 [email protected]